D. Dornan

发表

The ubiquitin ligase COP1 is a critical negative regulator of p53

Patrick Dowd, Vishva M. Dixit, G. Frantz, 2004, Nature.

ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage

Somasekar Seshagiri, Vishva M Dixit, S. Seshagiri, 2006, Science.

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control

L. Holmberg, A. Tutt, S. Pinder, 2013, BMC Genomics.

Dissecting cancer heterogeneity

J. Settleman, D. Dornan, 2011, Nature Biotechnology.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Christian Wiesmann, Pamela Chan, Ping Wu, 2009, The Journal of clinical investigation.

TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer

Ru-Fang Yeh, Richard Bourgon, Zachary Boyd, 2011, Science Signaling.

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data

Erich P Huang, J. Fridlyand, N. Lewin-Koh, 2010, BMC Cancer.

Advances in Brief COP 1 , the Negative Regulator of p 53 , Is Overexpressed in Breast and Ovarian Adenocarcinomas

G. Frantz, H. Koeppen, V. Dixit, 2004 .

Human De-Etiolated-1 Regulates c-Jun by Assembling a CUL4A Ubiquitin Ligase

R. Deshaies, Zemin Zhang, V. Dixit, 2004, Science.

Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study.

M. Karsdal, D. Dornan, D. Leeming, 2015, Cancer biomarkers : section A of Disease markers.

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.

Jeffrey T. Lau, A. Ebens, H. Koeppen, 2009, Blood.

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Sean C. Bendall, Michael N. Alonso, J. Melrose, 2020, Nature Cancer.

Inhibition of p 53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p 300

T. Hupp, D. Dornan, 2013 .

DCDT 2980 S , an anti-CD 22-Monomethyl Auristatin E antibody-drug conjugate , is a potential treatment for non-Hodgkins Lymphoma

Jeffrey T. Lau, D. Danilenko, A. Ebens, 2013 .

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

R. Yeh, O. Spleiss, D. Dornan, 2009 .

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

F. Bazan, V. Dixit, H. Maecker, 2010, Nature.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Zhi Wei, Hongye Liu, Wei Huang, 2018, Cancer discovery.

COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas

G. Frantz, H. Koeppen, V. Dixit, 2004, Cancer Research.

Predictive Biomarkers for Antibody–Drug Conjugates

J. Settleman, D. Dornan, 2013 .

miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer

D. Dornan, Peng Yue, R. Newman, 2013, PloS one.

miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer

R. Bourgon, R. Yeh, A. Adai, 2011, Science Signaling.

Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway

Michael O. Kelleher, K. Ball, D. Dornan, 2002, Oncogene.

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

Jeffrey T. Lau, R. Advani, S. de Vos, 2011, Science Translational Medicine.

Cancer: miRNA Addiction — Depending On Life's Little Things

J. Settleman, D. Dornan, 2010, Current Biology.

To respond or not to respond to CD40 agonism: That is the prediction

D. Dornan, Xiaoyan Shi, 2012, Oncoimmunology.

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

W. Hiddemann, R. Yeh, S. Bohlander, 2013, Blood.

Inactivation of TP 53 correlates with disease progression and low miR-34 a expression in previously treated chronic lymphocytic leukemia patients

W. Hiddemann, R. Yeh, S. Bohlander, 2013 .

Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53

T. Hupp, K. Ball, D. Dornan, 2004, Molecular and Cellular Biology.

The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53

T. Hupp, D. Dornan, H. Shimizu, 2003, Molecular and Cellular Biology.

DNA-dependent Acetylation of p53 by the Transcription Coactivator p300*

N. Perkins, T. Hupp, D. Dornan, 2003, The Journal of Biological Chemistry.

The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo *

T. Hupp, K. Ball, D. Dornan, 2002, The Journal of Biological Chemistry.

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

M. Karsdal, D. Dornan, D. Leeming, 2013, BMC Cancer.

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

M. Karsdal, C. Christiansen, D. Dornan, 2014, Cancer medicine.

Effect of FCGR2A and FCGR3A variants on CLL outcome.

R. Yeh, O. Spleiss, D. Dornan, 2010, Blood.

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

R. Advani, J. Winter, B. Cheson, 2008 .

Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300

T. Hupp, D. Dornan, 2001, EMBO reports.

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

R. Yeh, H. Döhner, M. Hallek, 2014, Blood.

Effect of FCGR2Aand FCGR3Avariants on CLL outcome

R. Yeh, O. Spleiss, D. Dornan, 2017 .

Effect of FCGR 2 A and FCGR 3 A variants on CLL outcome

R. Yeh, O. Spleiss, D. Dornan, 2010 .

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Jeffrey T. Lau, D. Danilenko, A. Ebens, 2013, Molecular Cancer Therapeutics.

Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models

Michael N. Alonso, E. Engleman, D. Dornan, 2019, Immunology.

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia

R. Yeh, D. Maisel, D. Dornan, 2015, Blood Cancer Journal.

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Michael N. Alonso, E. Perez, D. Juric, 2021 .

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

L. Rimsza, R. Fisher, T. Miller, 2009 .

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

D. Dornan, S. Marsters, A. Ashkenazi, 2009, The Journal of clinical investigation.